



## Myeloproliferative Diseases: From Diagnosis to Treatment Approach, through the Molecular Landscape

Guest Editor:

**Dr. Maura Nicolosi**

Department of Hematology,  
Azienda Ospedaliera  
Universitaria, Città della Salute e  
della Scienza di Torino, 28100  
Torino, Italy

Deadline for manuscript  
submissions:

**closed (15 November 2021)**

### Message from the Guest Editor

The advent of molecular biological analyses and the widely adoption of next-generation sequencing technology has allowed a deep classification of patients affected by myeloid diseases, especially in Philadelphia-negative myeloproliferative neoplasm (MPNs) in terms of prognosis and survival. Novel and strict classification of patients based on molecular, cytogenetic, and clinical aspects have upgraded the diagnosis, classification, and prognostication of patients, in the early days and during the natural history of the disease, guiding the treatment approach.

The purpose of this Special Issue is to discuss the novel developments of molecular biology in recent years regarding its utility in the different prognostic stratification of patients affected by myeloid disorders, such as primary myelofibrosis (PM), essential thrombocythemia (ET), polycythemia vera (PV), and chronic myeloid leukemia (CML). The value of deeper molecular analyses and the cytogenetic classification in guiding the treatment approaches is continuously under study to improve our knowledge.





# medicina

IMPACT  
FACTOR  
2.4

Indexed in:  
PubMed

CITESCORE  
3.3

an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian  
University of Health Sciences,  
Kaunas, Lithuania

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## Contact Us

---

*Medicina* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/medicina](http://mdpi.com/journal/medicina)  
[medicina@mdpi.com](mailto:medicina@mdpi.com)